Marinos CD. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol. 2008;4:557–67.

Article  Google Scholar 

Kazumoto I, Mayumi S, Kandai N, Rintaro M, Nao T, Koichi K, Kenichiro M, Kunihiko A, Koichi N, Yoshiyuki O, Shori T, Ryojiro T, Hiroshi K, Hidefumi N, Kenji I, Shuichi I, Yasuo O. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273–81.

Article  Google Scholar 

Jennifer CR, Mark H, Heather NR. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12:677–86.

Article  Google Scholar 

Hitoshi S, Krzysztof K, Jan N, Zina M, Andrew BH, Matthew BR, Robert JW, Francesco S, Jiri M, Ali GG, Bruce AJ. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–803.

Article  Google Scholar 

de la Torre I, Leandro MJ, Edwards JC, Cambridge G. Baseline serum immunoglobulin levels in patients with rheumatoid arthritis: relationships with clinical parameters and with B-cell dynamics following rituximab. Clin Exp Rheumatol. 2012;30:554–60.

PubMed  Google Scholar 

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC. A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol. 2017;28:1306–13.

Article  CAS  PubMed  Google Scholar 

Henrik EM, Daniela F, Claudia G, Christoph L, Karin R, Stefanie S, Eugen F, Capucine D, Hans-Peter T, Andreas R, Thomas D. Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood. 2010;116:5181–90.

Article  Google Scholar 

Khalaf K, Razzaque AA. Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev. 2020. https://doi.org/10.1016/j.autrev.2020.102466.

Article  Google Scholar 

Chisato U, Tomohiko N, Yuji T, Yoshitaka W, Koji S, Hitohiko M, Shuichiro F. A case of a 9-year-old girl who developed IgA nephropathy after rituximab administration for steroid-dependent minimal change nephrotic syndrome. JSPRF. 2019;39:111–4 ((in Japanese)).

Google Scholar 

Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol. 1998;18:425–9.

Article  CAS  PubMed  Google Scholar 

Diwakar L, Gorrie S, Richter A, Chapman O, Dhillon P, Al-Ghanmi F, Noorani S, Krishna MT, Huissoon A. Does rituximab aggravate pre-existing hypogammaglobulinaemia? J Clin Pathol. 2010;63:275–7.

Article  PubMed  Google Scholar 

Nihei Y, Haniuda K, Higashiyama M, Asami S, Iwasaki H, Fukao Y, Nakayama M, Suzuki H, Kikkawa M, Kazuno S, Miura Y, Suzuki Y, Kitamura D. Identification of IgA autoantibodies targeting mesangial cells redefines the pathogenesis of IgA nephropathy. Sci Adv. 2023. https://doi.org/10.1126/sciadv.add6734.

Article  PubMed  PubMed Central  Google Scholar 

Douglas DM, Julie K, Cheryl W, Adrian P, Urjana P, Elisa AP, Lesley W, Melissa AEL, Andrew JM, Kathy DM, York P, Lea N, Jeannette YL, Bruce AJ, Jan N, Ann R, Jennifer LG, Jeffrey LB. Mice overexpressing BAFF develop a commensal flora-dependent. IgA-associated nephropathy J Clim Invest. 2011;121:3991–4002.

Google Scholar 

Myette JR, Kano T, Suzuki H, Sloan SE, Szretter KJ, Ramakrishnan B, Adari H, Deotale KD, Engler F, Shriver Z, Wollacott AM, Suzuki Y, Pereira BJG. A Proliferation Inducing Ligand (APRIL) targeted antibody is a safe and effective treatment of murine IgA nephropathy. Kidney Int. 2019;96:104–16.

Article  CAS  PubMed  Google Scholar 

Therese V, Mikael H, Iva G, Wei Z, Marie W, Christina T, Vivianne M. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther. 2006;8:R167.

Article  Google Scholar 

O’Connor BP, Raman VS, Erickson LD, Cook WJ, Weaver LK, Ahonen C, Lin LL, Mantchev GT, Bram RJ, Noelle RJ. BCMA is essential for the survival of long-lived bone marrow plasma cells. J EXP Med. 2004;199:91–8.

Article  CAS  PubMed  PubMed Central  Google Scholar